You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsed and/or refractory

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed and/or Refractory Multiple Myeloma Trial in Köln (BMS-986453, Fludarabine, Cyclophosphamide)

Not yet recruiting
  • Relapsed and/or Refractory Multiple Myeloma
  • Köln, Germany
    Local Institution - 0017
Dec 4, 2023

Relapsed and/or Refractory Multiple Myeloma, Plasma Cell Leukemia in Relapse Trial in Shanghai (Biological)

Recruiting
  • Relapsed and/or Refractory Multiple Myeloma
  • Plasma Cell Leukemia in Relapse
  • Biological
  • Shanghai, Shanghai, China
    Shanghai Tongji Hospital
May 29, 2023

Belantamab Mafodotin Care Patterns in Relapsed and/or Refractory

Not yet recruiting
  • Multiple Myeloma
  • Durham, North Carolina
    Duke University Medical Center
Aug 8, 2023

Relapsed and/or Refractory Multiple Myeloma Trial in China (ICP-490)

Not yet recruiting
  • Relapsed and/or Refractory Multiple Myeloma
  • Beijing, Beijing, China
  • +4 more
Jan 30, 2023

Relapsed/Refractory Multiple Myeloma Trial (Isatuximab, Carfilzomib, Dexamethasone)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • (no location specified)
Feb 3, 2023

Solid Tumor Trial in Huntersville, San Antonio (IGM-7354)

Recruiting
  • Solid Tumor
  • Huntersville, North Carolina
  • +1 more
Jan 25, 2023

Relapsed and/or Refractory Multiple Myeloma Trial (CT0591CP Cells)

Not yet recruiting
  • Relapsed and/or Refractory Multiple Myeloma
  • CT0591CP Cells
  • (no location specified)
Aug 2, 2022

Multiple Myeloma Trial in United States (IGM-2644)

Recruiting
  • Multiple Myeloma
  • Duarte, California
  • +4 more
Jun 9, 2023

Multiple Myeloma Trial in Boston (BMS-986393, Alnuctamab, Mezigdomide)

Not yet recruiting
  • Multiple Myeloma
  • Boston, Massachusetts
  • +1 more
Nov 2, 2023

Long-term KRd in Relapsed and/or Refractory Multiple Myeloma

Not yet recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • (no location specified)
Aug 8, 2022

CBFA2T3-GLIS2-positive Acute Myeloid Leukemia, AML, Childhood, Relapsed Pediatric AML Trial (ELU001)

Not yet recruiting
  • CBFA2T3-GLIS2-positive Acute Myeloid Leukemia
  • +3 more
  • (no location specified)
Nov 14, 2022

Relapsed and/or Refractory B-cell Lymphoma Trial in Stanford, Baltimore, Houston (Cyclophosphamide, Fludarabine, KITE-363)

Recruiting
  • Relapsed and/or Refractory B-cell Lymphoma
  • Stanford, California
  • +2 more
Aug 16, 2022

Non-Hodgkin Lymphoma, Large B-cell Lymphoma Trial in Palo Alto (Axicabtagene Ciloleucel)

Not yet recruiting
  • Non-Hodgkin Lymphoma
  • Large B-cell Lymphoma
  • Axicabtagene Ciloleucel
  • Palo Alto, California
    Stanford University
Mar 20, 2023

Relapsed and/or Refractory Multiple Myeloma Trial in Worldwide (AMG 420)

Completed
  • Relapsed and/or Refractory Multiple Myeloma
  • AMG 420
  • Park Ridge, Illinois
  • +9 more
Dec 1, 2022

Multiple Myeloma Trial (BCMA-TGFß CAR-T cells (0.75 x10^6 cells/kg), BCMA-TGFß CAR-T cells (1 x 10^6 cells/kg), BCMA-TGFß CAR-T

Not yet recruiting
  • Multiple Myeloma
  • BCMA-TGFβ CAR-T cells (0.75 x10^6 cells/kg)
  • +3 more
  • (no location specified)
Jul 28, 2023

B-cell Non-Hodgkin Lymphoma (B-NHL), B-cell Acute Lymphoblastic Lymphoma (B-ALL) Trial (PIT565)

Not yet recruiting
  • B-cell Non-Hodgkin Lymphoma (B-NHL)
  • B-cell Acute Lymphoblastic Lymphoma (B-ALL)
  • PIT565
  • (no location specified)
Jun 13, 2022

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Carfilzomib, Cyclophosphamide, Dexamethasone)

Not yet recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • (no location specified)
Jun 8, 2023

Non Hodgkin Lymphoma Trial in New York, Clayton, Frankston (IPH6501)

Not yet recruiting
  • Non Hodgkin Lymphoma
  • New York, New York
  • +2 more
Oct 12, 2023

Refractory Multiple Myeloma, Relapse Multiple Myeloma Trial in Milwaukee (Belantamab mafodotin)

Recruiting
  • Refractory Multiple Myeloma
  • Relapse Multiple Myeloma
  • Belantamab mafodotin
  • Milwaukee, Wisconsin
    Froedtert & the Medical College of Wisconsin
Aug 3, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (Bortezomib, Metformin Hydrochloride,

Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Jacksonville, Florida
  • +1 more
Jan 5, 2023

Quality of Life in Relapsed and/or Refractory Multiple Myeloma

Active, not recruiting
  • Multiple Myeloma
    • Morrisville, North Carolina
      Local Institution
    May 12, 2022

    Multiple Myeloma Trial in Beijing, Nanjing, Tianjin (Isatuximab SAR650984)

    Active, not recruiting
    • Multiple Myeloma
    • Isatuximab SAR650984
    • Beijing, China
    • +2 more
    Aug 22, 2022

    Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Hangzhou (APRIL CAR-T cells)

    Recruiting
    • Multiple Myeloma in Relapse
    • Multiple Myeloma, Refractory
    • APRIL CAR-T cells
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital，College of Medicine, Zhejiang Univ
    May 3, 2022

    Multiple Myeloma Trial in Hangzhou, Wuhan (CART-BCMA)

    Recruiting
    • Multiple Myeloma
    • Hangzhou, China
    • +1 more
    Apr 23, 2022

    Relapsed or Refractory Multiple Myeloma Trial (Forimtamig, Carfilzomib, Daratumumab)

    Not yet recruiting
    • Relapsed or Refractory Multiple Myeloma
    • (no location specified)
    Sep 20, 2023